Jacques Le Lorier
About
In The Last Decade
Jacques Le Lorier
21 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 151
- Statistics, Probability and Uncertainty 281
- Economics and Econometrics 221
- Surgery 196
- General Health Professions 179
- Public Health, Environmental and Occupational Health 173
Countries citing papers authored by Jacques Le Lorier
This map shows the geographic impact of Jacques Le Lorier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Le Lorier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Le Lorier more than expected).
Fields of papers citing papers by Jacques Le Lorier
This network shows the impact of papers produced by Jacques Le Lorier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Le Lorier. The network helps show where Jacques Le Lorier may publish in the future.
Co-authorship network of co-authors of Jacques Le Lorier
This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Le Lorier. A scholar is included among the top collaborators of Jacques Le Lorier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Le Lorier. Jacques Le Lorier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 8 | |
| 3 | 5 | |
| 4 | 5 | |
| 5 | 1 | |
| 6 | 24 | |
| 7 | 8 | |
| 8 | 1 | |
| 9 | 45 | |
| 10 | 2 | |
| 11 | 2 | |
| 12 | Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. | 10 |
| 13 | Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. | 18 |
| 14 | 145 | |
| 15 | 15 | |
| 16 | 445 | |
| 17 | 56 | |
| 18 | 433 | |
| 19 | Gentamicin: use of a programmable calculator to determine dosages from pharmacokinetic data for individual patients. | 2 |
| 20 | 27 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.